Base Pair Biotechnologies, Inc.
9307 W. Broadway, Suite 390
Base Pair Biotechnologies offers researchers a total solution for developing aptamer based technologies. Our expertise and multiplexed approach to custom aptamer discovery allows us to deliver reagents at unprecedented speed and throughput. Scientists at Base Pair Biotechnologies have been studying aptamers and developing them on a research basis since 2004, besides academic and commercial collaborations they also are engaged in federally funded research projects involving aptamers.
Our Progressive Ownership Platform provides a low risk, low cost entry into aptamer development with varying levels of intellectual property transfer depending on need. Besides aptamer discovery we also provide additional aptamer services such as assay design, sandwich pairs, and kinetic evaluation. In 2010 CSO and Founder Dr. Bill Jackson co-authored, “Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets” for BCC Research.
We currently support researchers with applications ranging from ELISA, FACS, IHC, lateral flow, biosensor development and microfluidics, we are open to collaborations in novel aptamer research as well.
Base Pair Biotechnologies provides custom aptamer development and validation to targets of interest to researchers. We also have a portfolio of existing aptamers available at low cost for proof of principle experiments or commercialization.
Recently we launched an Aptamer Test Kit because as researchers ourselves we recognize that as scientists nothing validates an idea like doing the experiment yourself. The kit is available so that researchers can test one of our aptamers themselves in a pre-defined assay format.
Key Management Listings:
Bill Jackson PhD, Founder, President, and Chief Scientist
Bill Jackson serves as President and Chief Scientist of Base Pair Biotechnologies. Prior to formal spinout of aptamer discovery services under Base Pair, Bill guided numerous aptamer selections on both a service basis and for active research projects at parent company, BioTex, Inc. (also inHouston,TX).
Dr. Jackson is still partially employed by BioTex where he serves as a Senior Scientist on a number of synergistic research projects involving aptamers and biosensing. He joined BioTex in 2005 while concurrently finishing his Ph.D. in Chemical Engineering at nearby Universityof Houston. He has the somewhat rare distinction of funding his own doctoral dissertation serving as Principal Investigator on a NASA-funded SBIR grant. At the Universityof Houston, his research focused primarily on the development of novel nucleic acid diagnostics using both mass spectrometry and nucleic acid microarrays. Since that time, Dr. Jackson has served as Principal Investigator on 11+ SBIR grants and co-investigator on several more. He has been issued 4 U.S.patents with 10+ pending.
In previous employment Bill has been involved in the development of a wide variety of analytical chemistry equipment including instruments still in service aboard the International Space Station. Dr. Jackson received the B.S. in biomedical engineering fromTexasA&MUniversityin 1997 and a B.A. in Spanish in 1998.
In 2010 Dr. Jackson co-authored, “Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets” for BCC Research.
Base Pair Biotechnologies, Inc.